PEC3001
/ PharmaEssentia
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 02, 2026
Pre-clinical characterization of PEC3001, a PD-1 targeted IL-2Rα-active IL-2 immunocytokine with potent anti-tumor activity and a favorable safety profile.
(SITC 2026)
- No abstract available
Preclinical • Oncology • IL2
1 to 1
Of
1
Go to page
1